Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
4,998.09 -73.54 (-1.45%) Dow
37,767.40 -693.52 (-1.80%) Nasdaq
15,420.06 -292.69 (-1.86%) Bitcoin USD
63,402.19 -1,781.69 (-2.73%) CMC Crypto 200
1,375.45 -7.12 (-0.52%)
AnaptysBio, Inc. (ANAB)
| Previous close | 19.27 |
| Open | 19.01 |
| Bid | 18.91 x 200 |
| Ask | 19.19 x 100 |
| Day's range | 18.49 - 19.30 |
| 52-week range | 13.36 - 27.50 |
| Volume | |
| Avg. volume | 322,908 |
| Market cap | 512.38M |
| Beta (5Y monthly) | -0.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Actym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical eval
- GlobeNewswire
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab, our PD-1 agonist, with top-line data anticipated by mid 2025 and H1 2026, respectivelyIND filings for ANB033 (anti-CD122 antagonist) and ANB101 (BDCA2 modulator) anticipated Q2 2024 and H2 2
- GlobeNewswire
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference. Additionally, the company announced an upcoming presentation at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA, March 8-12, 2024. T
